BTIG Research set a $41.00 price target on Myriad Genetics (NASDAQ:MYGN) in a research report report published on Tuesday morning. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued research reports about the stock. ValuEngine raised shares of Myriad Genetics from a hold rating to a buy rating in a research report on Friday, November 10th. Stephens set a $45.00 price target on shares of Myriad Genetics and gave the stock a buy rating in a research report on Wednesday, January 3rd. Barclays reaffirmed a hold rating and set a $30.00 price target on shares of Myriad Genetics in a research report on Monday, January 8th. Zacks Investment Research cut shares of Myriad Genetics from a strong-buy rating to a hold rating in a research report on Friday, December 15th. Finally, Deutsche Bank increased their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the stock a hold rating in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. Myriad Genetics presently has an average rating of Hold and a consensus target price of $30.09.

Shares of Myriad Genetics (NASDAQ MYGN) traded down $0.26 during trading on Tuesday, hitting $35.79. The stock had a trading volume of 1,073,900 shares, compared to its average volume of 567,490. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $2,510.00, a P/E ratio of 24.18, a PEG ratio of 2.29 and a beta of 0.24. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company’s revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $0.23 earnings per share. sell-side analysts expect that Myriad Genetics will post 1.05 earnings per share for the current year.

In other Myriad Genetics news, insider Alexander Ford sold 3,031 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Richard M. Marsh sold 13,759 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $36.25, for a total transaction of $498,763.75. Following the completion of the transaction, the vice president now directly owns 136,385 shares in the company, valued at approximately $4,943,956.25. The disclosure for this sale can be found here. Insiders sold 30,290 shares of company stock worth $1,044,590 in the last three months. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Convergence Investment Partners LLC bought a new position in Myriad Genetics in the fourth quarter worth about $3,787,000. Louisiana State Employees Retirement System lifted its holdings in Myriad Genetics by 7.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 29,800 shares of the company’s stock worth $1,023,000 after acquiring an additional 2,100 shares during the last quarter. Parametric Portfolio Associates LLC lifted its holdings in Myriad Genetics by 5.2% in the third quarter. Parametric Portfolio Associates LLC now owns 353,673 shares of the company’s stock worth $12,796,000 after acquiring an additional 17,439 shares during the last quarter. TrimTabs Asset Management LLC lifted its holdings in Myriad Genetics by 17.2% in the third quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock worth $427,000 after acquiring an additional 1,728 shares during the last quarter. Finally, Shelton Capital Management bought a new position in Myriad Genetics in the third quarter worth about $238,000.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/17/myriad-genetics-mygn-pt-set-at-41-00-by-btig-research.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.